{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:35:05Z","timestamp":1782146105685,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","award":["21KJA150007"],"award-info":[{"award-number":["21KJA150007"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013280","name":"Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52273251"],"award-info":[{"award-number":["52273251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52473264"],"award-info":[{"award-number":["52473264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.actbio.2025.05.041","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:11:38Z","timestamp":1747393898000},"page":"641-652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Vincristine\/Volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9621-9738","authenticated-orcid":false,"given":"Qing","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-1555","authenticated-orcid":false,"given":"Huanli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2025.05.041_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.actbio.2025.05.041_bib0002","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute lymphoblastic leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.actbio.2025.05.041_bib0003","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.actbio.2025.05.041_bib0004","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.actbio.2025.05.041_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at md anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2025.05.041_bib0006","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMe2027937","article-title":"Chemotherapy-free treatment - a new era in acute lymphoblastic leukemia?","volume":"383","author":"Hoelzer","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.actbio.2025.05.041_bib0007","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jama.2021.1395","article-title":"Blinatumomab for treatment of children with high-risk relapsed B-cell acute lymphoblastic leukemia","volume":"325","author":"Shukla","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.actbio.2025.05.041_bib0008","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41551-020-00624-6","article-title":"Therapeutic vaccination against leukemia via the sustained release of co-encapsulated anti-PD-1 and a leukemia-associated antigen","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.actbio.2025.05.041_bib0009","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-018-0015-6","article-title":"A causal mechanism for childhood acute lymphoblastic leukaemia","volume":"18","author":"Greaves","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2025.05.041_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.actbio.2025.05.041_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2025.05.041_bib0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2020.10.013","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities","volume":"84","author":"Tran","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.actbio.2025.05.041_bib0013","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.actbio.2025.05.041_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114747","article-title":"Polo-like kinase 1 (PLK1) signaling in cancer and beyond","volume":"193","author":"Iliaki","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.actbio.2025.05.041_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2025.05.041_bib0016","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd3184","article-title":"Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy","volume":"9","author":"Strebhardt","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2025.05.041_bib0017","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.actbio.2021.10.043","article-title":"Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: a comparative study of molecular inhibitors and siRNA therapeutics","volume":"138","author":"Wang","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2025.05.041_bib0018","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/med.21392","article-title":"Spotlight on volasertib: preclinical and clinical evaluation of a promising PLK1 inhibitor","volume":"36","author":"Van den Bossche","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.actbio.2025.05.041_bib0019","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.1021\/acs.jmedchem.2c00614","article-title":"Polo-like kinase 1 inhibitors in human cancer therapy: development and therapeutic potential","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.actbio.2025.05.041_bib0020","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"Dohner","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2025.05.041_bib0021","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ijc.29725","article-title":"Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in ewing sarcoma cells","volume":"138","author":"Wei\u00df","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.actbio.2025.05.041_bib0022","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/cdd.2015.59","article-title":"Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs","volume":"22","author":"Hugle","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.actbio.2025.05.041_bib0023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2019.03.015","article-title":"Threatening cancer with nanoparticle aided combination oncotherapy","volume":"301","author":"Rawal","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2025.05.041_bib0024","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41565-022-01310-1","article-title":"Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma","volume":"18","author":"Detappe","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2025.05.041_bib0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","article-title":"Nanomedicine of synergistic drug combinations for cancer therapy \u2013 strategies and perspectives","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2025.05.041_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007787","article-title":"Daratumumab immunopolymersome-enabled safe and CD38-targeted chemotherapy and depletion of multiple myeloma","volume":"33","author":"Yu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.05.041_bib0027","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.actbio.2025.05.041_bib0028","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ebiom.2019.02.012","article-title":"A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma","volume":"41","author":"Wu","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.actbio.2025.05.041_bib0029","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/acs.biomac.1c01342","article-title":"CD38-directed vincristine nanotherapy for acute lymphoblastic leukemia","volume":"23","author":"Zhang","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2025.05.041_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101872","article-title":"Exogenous CD38 upregulation enables high-efficacy dually cascade targeted molecular therapy of leukemia","volume":"50","author":"Du","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.actbio.2025.05.041_bib0031","first-page":"499","article-title":"Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia","volume":"21","author":"Xia","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.actbio.2025.05.041_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123316","article-title":"Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis through stromal modulation","volume":"644","author":"Zhu","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.05.041_bib0033","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/10717544.2022.2048132","article-title":"Construction of pH-sensitive targeted micelle system co-delivery with curcumin and dasatinib and evaluation of anti-liver cancer","volume":"29","author":"Zeng","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.actbio.2025.05.041_bib0034","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.actbio.2024.11.024","article-title":"A self-assembling cytotoxic nanotherapeutic strategy for high drug loading and synergistic delivery of molecularly targeted therapies","volume":"191","author":"Zhang","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2025.05.041_bib0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","article-title":"The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo","volume":"8","author":"Chao","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2025.05.041_bib0036","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12935-022-02624-9","article-title":"Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine","volume":"22","author":"Dhyani","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.actbio.2025.05.041_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202209984","article-title":"Exogenous antigen upregulation empowers antibody targeted nanochemotherapy of leukemia","volume":"35","author":"Yue","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.05.041_bib0038","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/cas.14769","article-title":"Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer","volume":"112","author":"Lin","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.actbio.2025.05.041_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100759","article-title":"Inhibition of the PLK1-coupled cell cycle machinery overcomes resistance to oxaliplatin in colorectal cancer","volume":"8","author":"Yu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2025.05.041_bib0040","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1021\/acs.biomac.4c00561","article-title":"CXCR4-mediated codelivery of FLT3 and BCL-2 inhibitors for enhanced targeted combination therapy of FLT3-itd acute myeloid leukemia","volume":"25","author":"Yang","year":"2024","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2025.05.041_bib0041","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.actbio.2025.05.041_bib0042","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/nature08020","article-title":"CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia","volume":"459","author":"Buonamici","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2025.05.041_bib0043","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1158\/0008-5472.CAN-20-0034","article-title":"Monocyte-derived leukemia-associated macrophages facilitate extramedullary distribution of T-cell acute lymphoblastic leukemia cells","volume":"80","author":"Yang","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2025.05.041_bib0044","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acsanm.3c06253","article-title":"CD7 nanobody-based immuno-nanotoxin for targeted treatment of t-cell acute lymphoblastic leukemia","volume":"7","author":"Dong","year":"2024","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.actbio.2025.05.041_bib0045","first-page":"5263","article-title":"Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies","volume":"11","author":"Chen","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.actbio.2025.05.041_bib0046","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1158\/1538-7445.AM2023-3664","article-title":"Mechanism for bone marrow failure differs between acute myeloid and lymphoid leukemia","volume":"83","author":"Bertoli","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2025.05.041_bib0047","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1182\/blood-2022-155591","article-title":"Osteolytic bone lesions as an initial presenting manifestation of acute lymphoblastic leukemia in adults","volume":"140","author":"Al-Mashdali","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2025.05.041_bib0048","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR t cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2025.05.041_bib0049","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","article-title":"GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy","volume":"32","author":"Shi","year":"2024","journal-title":"Mol. Ther."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125003666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125003666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:01:20Z","timestamp":1774861280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125003666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"alternative-id":["S1742706125003666"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.05.041","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vincristine\/Volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}